Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

The impact of 27-hydroxycholesterol, a macrophage-synthesized estrogen receptor agonist, on breast cancer pathophysiology.

FY 2008-09

Summary
The most recent estimates indicate that the lifetime risk of getting breast cancer in women is around 1 in 10. Breast cancer can be categorized based on whether or not the estrogen receptor (ER) is present. In ER positive tumors, estrogen increases tumor growth. ER positive breast cancer can be treated with drugs that block the synthesis of estrogen the ER itself. Unfortunately, patients often develop resistance to these drugs for reasons that are poorly understood. Tumors are composed of both cancer cells and healthy immune cells. We know that the more immune cells present in breast cancer, the worse the prognosis for the patient. We think that these immune cells may be providing a source of 27-hydroxycholesterol (27HC), a chemical that we know can mimic estrogen. This tells us that 27HC made by immune cells likely contributes to the growth of ER positive breast cancer tumors and may lead to drug resistance. Here we propose to determine if 27HC, secreted by immune cells leads to breast cancer progression. We will use mice that spontaneously develop breast cancer and compare tumor growth between mice that have been genetically altered to 1) be unable to make 27HC, or 2) be unable to break down 27HC. In a second experiment we will take mice with cancer and treat them with either 27HC itself, or a drug that will inhibit 27HC synthesis. We will also measure cancer metastasis, blood vessel formation and certain important genes. Finally we will look more closely at how 27HC works by doing several experiments directly on human cancer cells. This study represents a paradigm shift away from focusing only on the synthesis of estrogen or the estrogen receptors as drug targets and may offer novel treatment options for patients with breast cancer. Collectively, the proposed studies will provide a clear understanding of the role of immune cell-synthesized 27HC in breast cancer, a prelude to the therapeutic exploitation of pathways that lead to its synthesis.
Program
CIHR Fellowship
Location
North Carolina, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
179583
Name
Nelson Erik R
Region
North Carolina
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The impact of 27-hydroxycholesterol, a macrophage-synthesized estrogen receptor agonist, on breast cancer pathophysiology.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
27-Hydroxycholesterol; Breast Cancer; Estrogen; Estrogen Receptor; Macrophage
Abstract
The most recent estimates indicate that the lifetime risk of getting breast cancer in women is around 1 in 10. Breast cancer can be categorized based on whether or not the estrogen receptor (ER) is present. In ER positive tumors, estrogen increases tumor growth. ER positive breast cancer can be treated with drugs that block the synthesis of estrogen the ER itself. Unfortunately, patients often develop resistance to these drugs for reasons that are poorly understood. Tumors are composed of both cancer cells and healthy immune cells. We know that the more immune cells present in breast cancer, the worse the prognosis for the patient. We think that these immune cells may be providing a source of 27-hydroxycholesterol (27HC), a chemical that we know can mimic estrogen. This tells us that 27HC made by immune cells likely contributes to the growth of ER positive breast cancer tumors and may lead to drug resistance. Here we propose to determine if 27HC, secreted by immune cells leads to breast cancer progression. We will use mice that spontaneously develop breast cancer and compare tumor growth between mice that have been genetically altered to 1) be unable to make 27HC, or 2) be unable to break down 27HC. In a second experiment we will take mice with cancer and treat them with either 27HC itself, or a drug that will inhibit 27HC synthesis. We will also measure cancer metastasis, blood vessel formation and certain important genes. Finally we will look more closely at how 27HC works by doing several experiments directly on human cancer cells. This study represents a paradigm shift away from focusing only on the synthesis of estrogen or the estrogen receptors as drug targets and may offer novel treatment options for patients with breast cancer. Collectively, the proposed studies will provide a clear understanding of the role of immune cell-synthesized 27HC in breast cancer, a prelude to the therapeutic exploitation of pathways that lead to its synthesis.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nelson, Erik R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~